Methotrexate treatment methods
AssigneeAldeyra Therapeutics, Inc.
InventorsStephen Gitu MACHATHA, Dean Eliott, Tomasz Stryjewski
Life of this patent
Estimating the term…
Abstract
The present disclosure provides compositions of methotrexate for ocular administration, including intravitreal administration, and use of the formulations for treating proliferative vitreoretinopathy (PVR), uveitis, macular edema, and uveitic macular edema.
Claims23
A method of treating proliferative vitreoretinopathy (PVR), comprising administering intravitreally to a subject in need thereof a composition comprising methotrexate at a concentration of about 5 mg/mL to about 12 mg/mL;
- sucrose at a concentration of about 7% w/v to about 12% w/v;
- and a phosphate buffer;
- wherein the volume of composition administered is about 20 μL to about 300 μL, and the incidence of secondary punctate keratitis in the subject is reduced.
(canceled)
-21. (canceled)
The method of claim 21, wherein the composition is administered before, during, or within 24 hrs of retinal detachment surgery, followed by administration about once a week for about 6-12 weeks.
The method of claim 22, wherein, after the administration about once a week, the composition is then administered about once every 2 weeks for up to 24 weeks. 24 (Original) The method of claim 23, wherein the administration about once every 2 weeks continues for about 8 weeks (about 4 administrations over about 8 weeks).
A method of treating proliferative vitreoretinopathy (PVR) comprising administering to a subject in need thereof a composition comprising methotrexate at a concentration of about 8 mg/mL;
- sucrose at a concentration of about 7.5% w/v, and a phosphate buffer at a pH of about 7.9 to about 9.0;
- wherein the volume of composition administered is 50 μL±10 μL;
- and the incidence of secondary punctate keratitis in the subject is substantially reduced.
-30. (canceled)
Dependencies are inferred from the claim text.